Janumet Tablet, Film Coated
NDC Package 0006-0577-03

11-digit billing NDC: 00006057703

Package Information

Janumet (sitagliptin and metformin hydrochloride) tablets is jANUMET® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitations of UseJANUMET should not be used in patients with type 1 diabetes mellitus.JANUMET has not been studied in patients with a history of pancreatitis. This formulation utilizes a tablet, film coated delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0006-0577 and is authorized under FDA application NDA022044.

Identification & Billing

NDC Package Code
0006-0577-03
Package Description
2 BOTTLE in 1 CARTON / 14 TABLET, FILM COATED in 1 BOTTLE (0006-0577-02)
Product Code
11-Digit Billing Format
00006057703
RxNorm Crosswalk
  • RxCUI: 2709488 - metFORMIN hydrochloride 1000 MG / SITagliptin phosphate 50 MG Oral Tablet
  • RxCUI: 2709488 - metformin hydrochloride 1000 MG / sitagliptin phosphate 50 MG Oral Tablet
  • RxCUI: 2709491 - metFORMIN hydrochloride 500 MG / SITagliptin phosphate 50 MG Oral Tablet
  • RxCUI: 2709491 - metformin hydrochloride 500 MG / sitagliptin phosphate 50 MG Oral Tablet
  • RxCUI: 861771 - Janumet 50 MG / 1000 MG Oral Tablet

Clinical Specifications

Proprietary Name
Janumet
Non-Proprietary Name
Sitagliptin And Metformin Hydrochloride
Substance Name
Sitagliptin Phosphate; Metformin Hydrochloride
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
JANUMET® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitations of UseJANUMET should not be used in patients with type 1 diabetes mellitus.JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET [see Warnings and Precautions (5.2)].

Regulatory & Marketing

Labeler Name
Merck Sharp & Dohme Llc
Product Type
Human Prescription Drug
FDA Application #
NDA022044
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-30-2007
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0006-0577). Click a package code to view its specific billing and regulatory data.

5 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK (0006-0577-01)
4 POUCH in 1 CARTON / 2 BLISTER PACK in 1 POUCH / 7 TABLET, FILM COATED in 1 BLISTER PACK
60 TABLET, FILM COATED in 1 BOTTLE
180 TABLET, FILM COATED in 1 BOTTLE
1000 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0006-0577-03 identifies a specific commercial package of 2 bottle in 1 carton / 14 tablet, film coated in 1 bottle (0006-0577-02) of Janumet, a human prescription drug labeled by Merck Sharp & Dohme Llc. This tablet, film coated is formulated for oral use and contains sitagliptin phosphate; metformin hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on March 30, 2007. The current certification is valid through December 31, 2027.

How is this Merck Sharp & Dohme Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00006057703. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0006-0577-03
11-Digit CMS (5-4-2)
00006-0577-03

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.